Training and Resources

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

KEYTRUDA® (pembrolizumab) in the adjuvant treatment of melanoma

KEYTRUDA as monotherapy is indicated for the adjuvant treatment of adults and adolescents aged 12 years and older with Stage IIB, IIC or III melanoma and who have undergone complete resection.

Expert on Demand in Melanoma

Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]

KEYTRUDA® (pembrolizumab) in the adjuvant treatment of Stage III melanoma

Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]

KEYTRUDA® (pembrolizumab) in the adjuvant treatment of Stage IIB and IIC melanoma

Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]

KEYTRUDA^® (pembrolizumab) in the treatment of advanced melanoma

KEYTRUDA as monotherapy is indicated for the treatment of adults and adolescents aged 12 years and older with advanced (unresectable or metastatic) melanoma.

KEYTRUDA® (pembrolizumab) in the treatment of advanced (unresectable or metastatic) melanoma

Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]

Patient education and support materials

KEYTRUDA® (pembrolizumab) monotherapy patient diary

Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website